Biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience
New Haven, CT
Joined August 2017
- Tweets530
- Following399
- Followers1.2K
- Likes73
Congratulations to our Co-Founder and CEO, Vimal Mehta, Ph.D., on being named to the @HartfordBiz2026 Power 25 Health Care list, recognizing leaders making a significant impact across Connecticut’s healthcare industry.
Learn more: hartfordbusiness.com/honoree…
#HealthcareInnovation
New Phase 3 SERENITY At-Home data @BioXcel_Tx presented at #ASCP2026 support BXCL501 for agitation associated with bipolar disorders or schizophrenia in the at-home setting, with reductions observed across all baseline severities. ir.bioxceltherapeutics.com/n… #Neuroscience
Today, the FDA has accepted our sNDA for IGALMI® for at-home use in treating acute agitation associated with bipolar disorders or schizophrenia. If approved, IGALMI would be the first FDA-approved outpatient option. PDUFA date: Nov 14, 2026. More: bit.ly/41m7r9U #FDA#BTI
We are excited to have received a positive recommendation from an independent Data Safety Monitoring Board to continue, as planned, our SERENITY At-Home trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Learn more. bit.ly/4kfwraI
It's estimated that more than 20 million people live with schizophrenia worldwide. Learn the facts about agitation associated with schizophrenia and show your support for World Schizophrenia Awareness Day 2025 on May 24. bit.ly/3kV6Erl
This #MentalAwarenessMonth,we’re reminding you about the 988 hotline that provides access to mental health support to everyone in the U.S. bit.ly/3Mmtrtr
We are pleased to report our first quarter 2025 financial results and announce that enrollment is complete in our SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. bit.ly/4j0th9s
This #MentalHealthMonth, we’re encouraging you to learn the facts about agitation, which is relatively common in adults with schizophrenia or bipolar disorders. Recognizing agitation earlier can help those affected manage symptoms before they escalate. bit.ly/3kV6Erl
We stand with those affected by mental illness to raise awareness and let them know they are not alone. Find resources to help people experiencing mental illness.
bit.ly/4jx6frB
While there is no consensus on the cause of agitation associated with bipolar disorder or schizophrenia, neurochemical imbalances and anatomical changes in the brain are believed to contribute to its development and clinical manifestations. Learn more. bit.ly/423hL7U
Expert consensus best practice guidelines recommend treating agitation related to bipolar disorder or schizophrenia with a combination of behavioral calming techniques, verbal de-escalation & medications voluntarily accepted by patients without coercion. bit.ly/423hL7U
Managing agitation associated with bipolar disorder or schizophrenia allows clinicians to talk to patients and determine the cause of symptoms. Learn more about cooperative de-escalation approaches. bit.ly/423hL7U
Research has shown that the foremost goal of treating agitation associated with bipolar disorder or schizophrenia with medication is to prevent harm to clinicians, patients, and self. Learn more about agitation treatment guidelines. bit.ly/423hL7U
We released our Q4 and full year 2024 financial results today! Learn more. bit.ly/3QQGciw
BioXcel Therapeutics strengthens cash position to advance SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia. Learn more. bit.ly/3XHrrlI
We are pleased with the progress of our SERENITY At-Home trial for the acute treatment of agitation associated with bipolar disorders or schizophrenia. Learn more. bit.ly/41wD5kx
We are pleased to share important clinical and business updates at BioXcel Therapeutics! Learn more. bit.ly/3CN7nHp
Thanks to Boehringer Ingelheim and BioCT for sponsoring the recent #AISummit. We are pleased that our VP of AI Drug Discovery, Friso Postma, joined a distinguished panel in sharing important insights about the impact of AI on pharma R&D.
Proud to announce that Friso Postma, our VP of AI Drug Discovery, will be speaking on a panel at Boehringer Ingelheim and BioCT’s #AISummit to discuss innovative applications of AI across research and development. Join us! lu.ma/oijbjl9r#AI #ResearchandDevelopment
We have just announced our Q3 2024 earnings. Learn more. bit.ly/3YQUaVj
